R. S. Baric

This study shows the SARS-CoV-2 D614G variant replicates more efficiently and transmits faster in hamsters than the wildtype virus.

This study characterizes the serotype-specific neutralizing antibody responses induced by the tetravalent dengue vaccine TAK-003 in humans and non-human primates, finding that DENV2 is immunodominant while DENV1, 3, and 4 responses are lower and cross-reactive.

The paper shows that baseline T cell immune signatures in mice predict virologic and disease outcomes upon SARS-CoV infection.

This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

The paper designs de novo ACE2 protein decoys to neutralize SARS-CoV-2 by blocking viral entry, showing high affinity and potent in vitro inhibition.

This paper evaluates an inactivated Newcastle disease virus expressing the SARS-CoV-2 spike protein as a cost-effective vaccine, showing immunogenicity and protective efficacy in animal models.

This paper develops a feeder-free organoid culture system for human distal lung progenitors and demonstrates SARS-CoV-2 infection of club cells in a novel in vitro model.

This paper describes NDV vector vaccines expressing SARS-CoV-2 spike protein that protect mice from viral challenge and can be produced cost-effectively in chicken eggs.

The paper uses cryo-EM and ASO experiments to study the SARS-CoV-2 FSE structure and its potential as an antiviral target, finding a complex tertiary structure but challenges in effective inactivation.

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine prevents SARS-CoV-2 infection and likely confers sterilizing immunity in mice.

This study uses high-density amplicon sequencing to show ongoing SARS-CoV-2 evolution and community spread in a Southern U.S. suburban area, identifying the D614G variant as dominant.

This study identifies conserved RNA secondary structures in SARS-like coronaviruses, suggesting their role in replication and pathogenesis and proposing their disruption as a vaccine strategy.

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 and related sarbecoviruses, highlighting a conserved epitope on the spike protein as a potential vaccine target.

This study rapidly identifies a potent human monoclonal antibody against SARS-CoV-2 that neutralizes the virus in animal models and shows promise for therapeutic use.

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

This paper develops a mouse-adapted SARS-CoV-2 model to evaluate medical countermeasures, showing age-related disease severity and the efficacy of IFN lambda-1a.

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.

This paper identifies CD300lf as the primary receptor for murine norovirus in vivo but shows it is not used by human norovirus.

This study demonstrates that the antiviral NHC/EIDD-2801 inhibits SARS-CoV-2 and multiple coronaviruses, showing therapeutic efficacy and oral bioavailability in mice.

This study identifies Muc4 as a protective factor in female mice against SARS-CoV pathogenesis, showing sex-specific effects without altering viral titers.

This study shows that proteolytic cleavage, not receptor binding, is the main barrier for two MERS-like bat coronaviruses to infect human cells, and that trypsin treatment can overcome this barrier.

This paper shows that GII.4 noroviruses preadapt and circulate undetected for years before causing a new pandemic, with changes in host immunity enabling spread rather than genetic changes alone.

The paper identifies STAT5 as a target of antagonism by WNV and ZIKV in human DCs, showing differential inhibition of Jak kinases compared to other flaviviruses.

This study shows combining NSP16 mutation with other attenuating mutations creates a safe and effective live-attenuated coronavirus vaccine that works in aged mice and against heterologous challenges.

This study shows that disrupting MERS-CoV NSP16's 2O methyl-transferase activity attenuates viral pathogenesis and provides a live attenuated vaccine platform.